Monika Scheer
Overview
Explore the profile of Monika Scheer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Koscielniak E, Ljungman G, Kazanowska B, Niggli F, Sparber-Sauer M, Handgretinger R, et al.
EClinicalMedicine
. 2024 Dec;
78:102957.
PMID: 39687431
Background: Rhabdomyosarcoma and other soft tissue sarcomas (STS) with high-risk features are still associated with an unsatisfactory outcome. We evaluated the efficacy of oral maintenance therapy added at the end...
2.
Papyan R, Hovsepyan S, Hoveyan J, Hovhannisyan S, Arakelyan T, Tamamyan G, et al.
J Cancer Policy
. 2024 Dec;
43:100530.
PMID: 39672462
Purpose: Musculoskeletal sarcomas are a rare group of malignant neoplasms, accounting for approximately 12 % of all malignant neoplasms among children. Childhood cancer outcomes vary between developed and developing countries...
3.
Kern L, Henssen A, Eggert A, Scheer M
Cancer Med
. 2024 Oct;
13(20):e70348.
PMID: 39463067
Background: Rhabdomyosarcoma (RMS) is a rare malignant soft tissue sarcoma (STS), accounting for almost 50% of pediatric STSs. Due to its heterogeneity, RMS presents challenges in diagnosis and treatment, with...
4.
Pusch F, Dorado Garcia H, Xu R, Gurgen D, Bei Y, Bruckner L, et al.
Mol Cancer Ther
. 2023 Dec;
23(4):507-519.
PMID: 38159110
The small-molecule inhibitor of ataxia telangiectasia and Rad3-related protein (ATR), elimusertib, is currently being tested clinically in various cancer entities in adults and children. Its preclinical antitumor activity in pediatric...
5.
Koscielniak E, Timmermann B, Munter M, Weclawek-Tompol J, Ladenstein R, Niggli F, et al.
J Clin Oncol
. 2023 Sep;
41(31):4916-4926.
PMID: 37725766
Purpose: To analyze and compare the indications, doses, and application methods of radiotherapy (RT) and their influence on prognosis of patients with localized rhabdomyosarcoma (RMS). Methods: One thousand four hundred...
6.
Tramsen L, Bochennek K, Sparber-Sauer M, Salzmann-Manrique E, Scheer M, Dantonello T, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046711
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma (STS) in childhood. Whereas more than 90% of patients with localized low-risk RMS can be cured, metastatic RMS have a dismal...
7.
Dorado Garcia H, Pusch F, Bei Y, von Stebut J, Ibanez G, Guillan K, et al.
Nat Commun
. 2022 Jul;
13(1):4297.
PMID: 35879366
Despite advances in multi-modal treatment approaches, clinical outcomes of patients suffering from PAX3-FOXO1 fusion oncogene-expressing alveolar rhabdomyosarcoma (ARMS) remain dismal. Here we show that PAX3-FOXO1-expressing ARMS cells are sensitive to...
8.
Scheer M, Hallmen E, Vokuhl C, Fuchs J, Tunn P, Munter M, et al.
J Cancer Res Clin Oncol
. 2022 Jun;
149(5):1717-1731.
PMID: 35687182
Purpose: Optimization of local therapies in synovial sarcoma (SS) considered unresectable at diagnosis is needed. We evaluated the effects of neoadjuvant versus adjuvant radiation versus surgery only on long-term outcomes....
9.
Thorwarth A, Haase K, Roefzaad C, Pajtler K, Schramm K, Hauptmann K, et al.
JCO Precis Oncol
. 2022 May;
6:e2100283.
PMID: 35613412
No abstract available.
10.
Koscielniak E, Blank B, Vokuhl C, Kazanowska B, Ladenstein R, Niggli F, et al.
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205646
We report here the results of the prospective, non-randomized, historically controlled CWS-2002P study in patients ≤ 21 years with localized RMS developed with the aim to improve the long-term outcome...